Abstract: The present invention includes a novel series of host materials for OLEDs based on substituted fused 1,2,4-triazines. The compounds of the invention may improve the device EQE and lifetime.

Abstract: Method, system, device and medium for determining a blood flow velocity in a vessel are provided. An example method includes receiving a 3D model of the vessel, which is reconstructed based on X-ray angiography images of the vessel. The method further includes specifying a segment of the 3D model by a start landmark and a termination landmark. Moreover, the method includes determining the blood flow velocity based on length of the segment and perfusion time for the segment by normalizing the blood flow velocity to correspond to a cardiac cycle. The method has a better accuracy in calculating blood flow velocity, and requires no additional modalities other than the original X-ray angiogram sequences used to visualize coronary arteries.

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Abstract: Provided are compounds of formula Ir(LA)m(LB)n, where m and n are each independently 1 or 2; and m+n=3; where LA has a structure of Formula I and LB has a structure of Formula II that are useful as emitters in OLEDs. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.

Abstract: Provided is a method for treating gastric cancer by blocking a CCL28 chemotactic pathway. Specifically, provided is a use of a CCL28 gene or CCL28 protein for preparing a reagent or a kit for testing gastric cancer. The gastric cancer has an abnormal up-regulated expression of both a Wnt/?-catenin signaling pathway and molecules related to CCL28 chemokine. Also provided are a testing kit, a use of a pharmaceutical composition, and a method for inhibiting the growth of cancer cells in vivo and in vitro.

Abstract: Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.

Abstract: A compound comprising a ligand LA, having a structure of Formula I, is provided. In Formula I, A1 to A8 are each independently CR or N; at least two adjacent ones of A1 to A8 are CR and the Rs are joined together to form a six-membered ring fused to ring A or ring C; X is O, S, or Se; each R and RB is independently hydrogen or a substituent; any adjacent substituents are optionally joined or fused into a ring; the ligand LA is coordinated to a metal M; the metal M is bonded to ring A through a M-C bond; the metal M can be coordinated to other ligands; and the ligand LA is optionally linked with other ligands. Formulations, OLEDs, and consumer products containing such compounds are also disclosed.

Abstract: A compound, Ir(LA)m(LB)3-m, having a structure of Formula I, is provided. In Formula I, each of moiety A and moiety C is independently a 5- or 6-membered ring or a polycyclic fused ring system comprising 5- or 6-membered rings; moiety B is a 5-membered heterocyclic ring; Z1, Z2, and Z3 are C or N; m is 1 or 2; at least one of R1, R2, R3, R4 has a structure of Formula II, or is a 5-membered heterocyclic ring; each of X1, X2, X3, X4, and X5 is CR or N; each of R1, R2, R3, R4, RA, RB, RC, and R is hydrogen or a General Substituent; at least one of R1a, R2a, R3a, R4a, R5a is cycloalkyl, alkyl, silyl, germyl, deuterated variants thereof, fluorinated variants thereof, and combinations thereof. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A neutral compound including a first ligand LA represented by Formula I or Formula II is disclosed.

Abstract: Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein ring A, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.

Abstract: A compound having a Pt tetradentate structure of Formula 1, is provided. In the structure of Formula 1, rings C and D each independently represent 5- or 6-membered carbocyclic or heterocyclic ring; L1, L2, and L3 are each independently a direct bond, BR, NR, PR, O, S, Se, C?O, S?O, SO2, SiRR?, GeRR?, alkyl, cycloalkyl, or a combination thereof; the sum of n1 and n2 is 1 or 2; X is selected from NRE, O, S, and Se; X3 and X4 each independently carbon or nitrogen; and one of Q1, Q3, and Q4 is oxygen, and the remaining two of Q1, Q3, and Q4 each represents a direct bond. Formulations and devices, such as an OLEDs, that include the compound of Formula 1 are also described.

Abstract: A heteroleptic compound having a Formula Ir(LA)m(LB)3-m, having a structure of Formula I is disclosed. In Formula I, m is 1 or 2; moieties A, C, and D are each independently monocyclic rings or polycyclic fused ring structures; each R1, R2, RA, RB, RC, RD, and RE is independently hydrogen or a substituent; if moiety A is a monocyclic 6-membered ring, then the RA para to N of ring A is not an aryl group; at least one of R1 and R2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, and combinations thereof; and adjacent substituents can be joined to form a ring. OLEDs, consumer products, and formulations including the heteroleptic compound are also disclosed.

Abstract: The present disclosure provides for an organic electroluminescent device (OLED) including an anode; a cathode; and an emissive layer, disposed between the anode and the cathode. The emissive layer includes a phosphorescent dopant, a first host, and a second host, wherein the first host transports holes, the second host transports electrons, and the first host is fully or partially deuterated. Consumer products that include the OLED are also provided.

Abstract: Heteroleptic compounds having a Formula Ir(LA)m(LB)3-m, having the structure of Formula I or Formula II, are described. In Formula I and Formula II, moiety B is a polycyclic fused ring structure comprising at least four rings; ring C is a 5- or 6-membered aromatic ring; moieties D and E are independently a monocyclic or polycyclic fused ring structure; Z1 and Z2 are each independently C or N; each RA, RB, RC, RD, and RE is hydrogen or a General Substituent; and when ring C is a phenyl ring, RC collectively comprises two or more C atoms. Formulations, OLEDs, and consumer products incorporating the compounds are also described.

Abstract: Novel organic metal complexes containing fused isoquinoline type ligands useful as emitters for near infrared OLED devices are disclosed.

Abstract: The present invention includes a novel series of host materials for OLEDs based on substituted fused 1,2,4-triazines, represented by Formula I. The invention also includes an organic light-emitting device comprising an anode, a cathode, and an organic layer, disposed between the anode and the cathode, comprising a compound of Formula I. The compounds of the invention may improve the device EQE and lifetime.

Abstract: A method may include wet ball milling a plurality of iron nitride nanoparticles in the presence of a surface active agent to modify a surface of the plurality of iron nitride nanoparticles and form a plurality of surface-modified iron nitride nanoparticles for a variety of biomedical applications and soft magnetic materials related applications.

Abstract: Compounds containing indolocarbazole compounds of Formula I or Formula II comprising terphenyl groups and compounds of Formula III comprising triazine groups are disclosed in this application. These compounds are useful for application in organic electroluminescent devices.

Abstract: A compound having a structure of is disclosed. In these formulas, each R1, R2, and R3 is independently selected from hydrogen, alkyl, and aryl; at least one of R1 and R2 is a branched alkyl containing at least 4 carbon atoms, where the branching occurs at a position further than the benzylic position; where R1 and R3 are mono-, di-, tri-, tetra-, or no substitutions; and R2 is mono-, di-, or no substitutions. Heteroleptic iridium complexes including such compounds, and devices including such compounds are also disclosed.

Abstract: The present disclosure is directed to a method and system for automatically predicting a physiological parameter based on images of vessel. The method includes receiving the images of a vessel acquired by an imaging device. The method further includes determining a sequence of temporal features at a sequence of positions on a centerline of the vessel based on the images of the vessel, and determining a sequence of structure-related features at the sequence of positions on the centerline of the vessel. The method also includes fusing the sequence of structure-related features and the sequence of temporal features at the sequence of positions respectively. The method additionally includes determining the physiological parameter for the vessel at the sequence of positions, by using a sequence-to-sequence neural network configured to capture sequential dependencies among the sequence of fused features.